Speciality: Pediatrics
Description:
A warm welcome to all the medical professionals in this interesting session on Arthritis and children: What is JIA?
Juvenile idiopathic arthritis (JIA) is the most common type of arthritis affecting children and adolescents under the age of 16. It is an autoimmune condition in which the body’s immune system mistakenly attacks its own tissues, leading to inflammation in the joints. This results in symptoms such as joint pain, swelling, stiffness, and reduced mobility. JIA can affect one or multiple joints and, in some cases, may also involve other organs, such as the eyes or skin.
There are several subtypes of JIA, each with different characteristics and levels of severity. While the exact cause is unknown, a combination of genetic and environmental factors is believed to play a role. Early diagnosis and treatment are crucial in managing JIA, as they can prevent long-term joint damage and improve the child’s quality of life. Treatment typically includes medications like NSAIDs, DMARDs, or biologics, along with physical therapy to maintain joint function and mobility.
Therefore, get an overall knowledge of arthritis and children: what is JIA?
See More Webinars @ Hidoc Webinars
1.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
2.
FDA approves Blenrep for relapsed or refractory multiple myeloma
3.
X-ray and radar technology combined to reduce cancer screening risks
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Researchers discuss HER2-low and HER2-zero in breast cancer
1.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
2.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
3.
The New Era of Oncology: Key Updates and Clinical Insights
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation